BRAF Mutations in NSCLC – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

BRAF mutations are rare in non-small cell lung cancer (NSCLC), occurring in about 1-5% of cases. However, they are most common in lung adenocarcinoma, a specific type of NSCLC. The most common BRAF mutation is V600E, found in more than 50% of cases with a BRAF mutation. V600E BRAF mutation is also the most common BRAF mutation in melanoma, a type of skin cancer. In melanoma, V600E BRAF mutation is associated with a significant dependency on MEK activity. This means cells with V600E BRAF mutation depend highly on the MEK protein to grow and survive. This provides a rational therapeutic strategy for V600E BRAF-mutant melanoma, as drugs that block MEK activity can effectively kill these cells. In lung adenocarcinoma, the frequency of V600E BRAF mutation is lower, at 1.5-2.8%. However, growing evidence shows that BRAF inhibitors, such as vemurafenib and dabrafenib, can effectively treat lung adenocarcinoma with V600E BRAF mutation. BRAF mutations are rare in NSCLC but are most common in lung adenocarcinoma. The V600E BRAF mutation is the most common in both NSCLC and melanoma. Promising targeted therapies are available for patients with V600E BRAF-mutant lung adenocarcinoma and melanoma.

 

Thelansis’s “BRAF Mutations in NSCLC Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential BRAF Mutations in NSCLC treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of BRAF Mutations in NSCLC across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

BRAF Mutations in NSCLC Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: BRAF Mutations in NSCLC – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: BRAF Mutations in NSCLC, BRAF Mutations in NSCLC market outlook, BRAF Mutations in NSCLC competitive landscape, BRAF Mutations in NSCLC market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)